Scarica l'app Stockscreener
3.17
2.76%
-0.09
Precedente Chiudi:
$3.26
Aprire:
$3.16
Volume 24 ore:
14,516
Relative Volume:
0.95
Capitalizzazione di mercato:
$57.46M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-4.4698
EPS:
-0.7092
Flusso di cassa netto:
-
1 W Prestazione:
-10.70%
1M Prestazione:
+3.59%
6M Prestazione:
-38.68%
1 anno Prestazione:
-30.63%
Intervallo 1D:
$3.07
$3.2486
Intervallo di 1 settimana:
$3.07
$3.84
Portata 52W:
$2.5209
$7.00
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Nome
Alterity Therapeutics Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ATHE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
3.17 | 59.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-03 | Downgrade | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | Iniziato | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr Borsa (ATHE) Ultime notizie
Compass Minerals International, Inc. (NYSE:CMP) Receives $22.00 Consensus Price Target from Analysts - Defense World
Benjamin Edwards Inc. Acquires 2,629 Shares of iShares Russell 1000 Value ETF $IWD - Defense World
AOT Growth & Innovation ETF (NASDAQ:AOTG) Short Interest Update - Defense World
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Sees Significant Drop in Short Interest - Defense World
CaixaBank (OTCMKTS:CAIXY) Hits New 52-Week High – Still a Buy? - Defense World
ProShares Short S&P 500 (NYSEARCA:SH) Sets New 1-Year Low – Here’s Why - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Alterity Therapeutics Ltd (ADR) trading halted, news pending - MSN
Insights: Alterity Therapeutics Ltd (ASX:ATH) - smallcaps.com.au
Antalpha Platform Holding Company (NASDAQ:ANTA) Short Interest Update - Defense World
Contrasting Alterity Therapeutics (NASDAQ:ATHE) & BioHarvest Sciences (NASDAQ:BHST) - Defense World
CapEx per share of Alterity Therapeutics Ltd. Sponsored ADR – NASDAQ:ATHE - TradingView
Alterity Therapeutics stock rises after positive MSA trial data presented at conference - Investing.com
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Finviz
Alterity Therapeutics (NASDAQ:ATHE) Shares Down 0.5% – What’s Next? - Defense World
Alterity Therapeutics presents ATH434-201 Phase 2 data - TipRanks
ASX recovers to shed just 0.13pc as healthcare and gold drags - Geelong Advertiser
Alterity Therapeutics raises A$20M in strategic placement - MSN
Alterity CEO to provide corporate update on ATH434 development - Investing.com
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity secures funding to advance MSA drug development - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
- SEC.gov
Alterity Therapeutics LtdADR (ATHE) News, Articles, Events & Latest Updates - Stocktwits
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology By Investing.com - Investing.com India
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
Ernexa Therapeutics (ERNA) Short Interest Ratio and Volume 2025 - MarketBeat
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy - Barchart.com
Trading Halts Explained - MarketBeat
IM Cannabis (IMCC) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Purple Biotech (PPBT) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
ATHE Financial Statements & ChartsAlterity Therapeutics LtdAdr MacroTrends - CMLviz
ATHE Pivot Points, Technical Analysis and Moving AveragesAlterity Therapeutics LtdAdr Technicals - CMLviz
Check up: A good fortnight to be a small cap health investor - Stockhead
Genprex (GNPX) Short Interest Ratio and Volume 2025 - MarketBeat
iBio (IBIO) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Integrated BioPharma (INBP) Short Interest Ratio and Volume 2025 - MarketBeat
ESSA Pharma (EPIX) Short Interest Ratio and Volume 2025 - MarketBeat
Immuron (IMRN) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Check up: Maybe next week will be better? - Stockhead
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
Check up: Pot, takeovers, and COVID-19 are making investors happy - Stockhead
Maxim Group Analyst Recommendations & Stock Picks - MarketBeat
ATHE Stock Price | Alterity Therapeutics Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
ATH Stock Price and Chart — ASX:ATH - TradingView
ATHE Stock Price and Chart — NASDAQ:ATHE - TradingView — Track All Markets
A Full List of Australia ADRs - Investing.com Canada
Alterity Therapeutics Ltd Adr Azioni (ATHE) Dati Finanziari
Non sono disponibili dati finanziari per Alterity Therapeutics Ltd Adr (ATHE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):